JP2017514860A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514860A5
JP2017514860A5 JP2016566689A JP2016566689A JP2017514860A5 JP 2017514860 A5 JP2017514860 A5 JP 2017514860A5 JP 2016566689 A JP2016566689 A JP 2016566689A JP 2016566689 A JP2016566689 A JP 2016566689A JP 2017514860 A5 JP2017514860 A5 JP 2017514860A5
Authority
JP
Japan
Prior art keywords
glp
inhibitor
function
seq
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016566689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514860A (ja
JP6672175B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/059811 external-priority patent/WO2015169789A1/en
Publication of JP2017514860A publication Critical patent/JP2017514860A/ja
Publication of JP2017514860A5 publication Critical patent/JP2017514860A5/ja
Application granted granted Critical
Publication of JP6672175B2 publication Critical patent/JP6672175B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016566689A 2014-05-07 2015-05-05 Ｇｌｐ−１及び抗ｉｌ−２１を使用した１型糖尿病の治療 Active JP6672175B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461989841P 2014-05-07 2014-05-07
US61/989,841 2014-05-07
EP14169596.5 2014-05-23
EP14169596 2014-05-23
EP14189732.2 2014-10-21
EP14189732 2014-10-21
PCT/EP2015/059811 WO2015169789A1 (en) 2014-05-07 2015-05-05 Treatment of diabetes type 1 using glp-1 and anti-il-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019229235A Division JP6824373B2 (ja) 2014-05-07 2019-12-19 Ｇｌｐ−１及び抗ｉｌ−２１を使用した１型糖尿病の治療

Publications (3)

Publication Number Publication Date
JP2017514860A JP2017514860A (ja) 2017-06-08
JP2017514860A5 true JP2017514860A5 (https=) 2018-05-31
JP6672175B2 JP6672175B2 (ja) 2020-03-25

Family

ID=54392180

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566689A Active JP6672175B2 (ja) 2014-05-07 2015-05-05 Ｇｌｐ−１及び抗ｉｌ−２１を使用した１型糖尿病の治療

Country Status (9)

Country Link
US (1) US10105442B2 (https=)
EP (1) EP3139948B1 (https=)
JP (1) JP6672175B2 (https=)
CN (1) CN106999553B (https=)
PL (1) PL3139948T3 (https=)
RS (1) RS60316B1 (https=)
SI (1) SI3139948T1 (https=)
TW (1) TWI668010B (https=)
WO (1) WO2015169789A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017149109A1 (en) * 2016-03-04 2017-09-08 Novo Nordisk A/S Liraglutide in diabetic foot ulcer
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2025257327A1 (en) 2024-06-13 2025-12-18 Almirall, S.A. Therapeutic approaches for the management of hidradenitis suppurativa

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL128332A0 (en) * 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
ES2629395T3 (es) * 2001-10-04 2017-08-09 Genetics Institute, Llc Métodos y composiciones para modular la actividad de la interleucina-21
EP1515749B1 (en) 2002-06-14 2012-08-15 Novo Nordisk A/S Combined use of a modulator of cd3 and a glp-1 compound
WO2005023291A2 (en) 2003-09-11 2005-03-17 Novo Nordisk A/S Use of glp1-agonists in the treatment of patients with type i diabetes
CN100444898C (zh) * 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
EP2298337B1 (en) * 2003-12-09 2017-02-22 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
EP1841448A2 (en) 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP1883417A2 (en) 2005-05-25 2008-02-06 Curedm Inc. Peptides, derivatives and analogs thereof, and methods of using same
CN101258163B (zh) * 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
CA2658678A1 (en) 2005-08-06 2007-02-15 Gerald J. Prud'homme Composition and method for prevention and treatment of type i diabetes
PL1971362T3 (pl) * 2005-08-19 2015-05-29 Amylin Pharmaceuticals Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
CN101291685A (zh) * 2005-08-19 2008-10-22 安米林药品公司 治疗糖尿病和降低体重的毒蜥外泌肽
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008028914A1 (en) 2006-09-07 2008-03-13 Nycomed Gmbh Combination treatment for diabetes mellitus
JP5511654B2 (ja) * 2007-05-31 2014-06-04 ゲンマブ エー／エス 分子操作により得られた組換え非グリコシル化一価半抗体
DK2193142T3 (da) * 2007-08-30 2015-04-20 Curedm Group Holdings Llc Præparater og fremgangsmåder til anvendelse af pro-øcellepeptider og analoger dertil
EP2190872B1 (en) * 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US7883700B2 (en) 2007-12-07 2011-02-08 Zymogenetics, Inc. Anti-human IL-21 monoclonal antibodies
RU2517135C2 (ru) * 2008-05-07 2014-05-27 Меррион Рисерч Iii Лимитед Композиции пептидов и способы их получения
CN102131516B (zh) * 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
MY180661A (en) * 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
WO2011106558A1 (en) 2010-02-24 2011-09-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for autoimmune disease diagnosis, prognosis, and treatment
WO2012098113A1 (en) 2011-01-17 2012-07-26 Novo Nordisk A/S Il-21 ligands
CA2830660A1 (en) * 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
CN103702721A (zh) * 2011-05-31 2014-04-02 诺沃—诺迪斯克有限公司 Il-21表位和il-21配体
US20140178396A1 (en) 2012-12-21 2014-06-26 Novo Nordisk A/S Treatment of cardiovascular diseases
EP2746292A1 (en) 2012-12-21 2014-06-25 Novo Nordisk A/S Anti-IL21 antibodies for use in the treatment of nephropathies

Similar Documents

Publication Publication Date Title
JP2018515088A5 (https=)
PE20240215A1 (es) Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
PE20231842A1 (es) Coagonistas de los receptores de glp-1 y gip
JP2016527286A5 (https=)
JP2016512213A5 (https=)
JP2016526012A5 (https=)
JP2016501839A5 (https=)
JP2018510132A5 (https=)
PE20200926A1 (es) Peptidos analogos de incretina
IL299282A (en) Enhanced variable complexes of immunoglobulins
JP2017528419A5 (https=)
AR093903A1 (es) Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad
JP2014501510A5 (https=)
JP2014524908A5 (https=)
PE20170940A1 (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer
JP2014525901A5 (https=)
HRP20170890T1 (hr) Suagonisti glukagonskog/glp-1 receptora
SG194717A1 (en) High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants againstischemic brain damage and for treatment of pain
BR112015032875A2 (pt) derivados de peptídeos do tipo glp-1, e usos dos mesmos
JP2017536337A5 (https=)
JP2018538356A5 (https=)
JP2017514860A5 (https=)
PE20181897A1 (es) Inmunoterapia contra el melanoma y otros tipos de cancer
CL2020003292A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)
JP2014506259A5 (https=)